NASDAQ · BAX
Healthcare · Medical - Instruments & Supplies
$23.00
Down-$0.50 (-2.13%)
Updated Oct 31, 2026, 6:08 PM
SID Score
5.2/10
Composite research score
Smart Money
47/100
Neutral
Price performance · BAX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
BAX closed at $23.00 after 21 trading sessions, down 2.09% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $23.59 | $23.59 | $22.495 | $23.00 | 11.82M |
| Oct 29, 2026 | $26.00 | $26.10 | $23.37 | $23.50 | 15.67M |
| Oct 28, 2026 | $25.11 | $26.025 | $24.93 | $25.46 | 12.43M |
| Oct 27, 2026 | $25.20 | $25.25 | $24.81 | $24.92 | 5.49M |
| Oct 26, 2026 | $25.62 | $25.62 | $25.06 | $25.29 | 4.04M |
| Oct 23, 2026 | $25.71 | $25.71 | $25.20 | $25.30 | 4.94M |
| Oct 22, 2026 | $24.73 | $25.705 | $24.68 | $25.65 | 5.21M |
| Oct 21, 2026 | $24.36 | $24.83 | $24.26 | $24.70 | 5.38M |
| Oct 20, 2026 | $25.08 | $25.23 | $23.62 | $24.51 | 12.18M |
| Oct 19, 2026 | $25.09 | $25.45 | $24.90 | $24.99 | 5.35M |
| Oct 16, 2026 | $25.95 | $25.985 | $25.1326 | $25.28 | 4.41M |
| Oct 15, 2026 | $25.25 | $25.885 | $25.22 | $25.76 | 4.51M |
| Oct 14, 2026 | $24.86 | $25.04 | $24.585 | $24.80 | 5.21M |
| Oct 13, 2026 | $25.06 | $25.26 | $24.52 | $24.89 | 3.25M |
| Oct 12, 2026 | $24.44 | $24.85 | $24.34 | $24.78 | 5.23M |
| Oct 9, 2026 | $23.93 | $24.465 | $23.84 | $24.35 | 3.01M |
| Oct 8, 2026 | $23.97 | $24.14 | $23.50 | $23.90 | 7.56M |
| Oct 7, 2026 | $24.20 | $24.60 | $23.82 | $23.97 | 4.77M |
| Oct 6, 2026 | $24.32 | $24.42 | $23.915 | $24.36 | 6.52M |
| Oct 5, 2026 | $23.46 | $24.285 | $23.235 | $24.22 | 10.16M |
| Oct 2, 2026 | $23.84 | $23.85 | $23.40 | $23.49 | 4.81M |
The latest Smart Investors Daily articles mentioning BAX.
Company
Market Activity
Research & News
BAX research
Company profile and research snapshot.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 30, 2026 | JP Morgan | Neutral | — |
| Oct 30, 2026 | Wells Fargo | Equal-Weight | — |
| Oct 7, 2026 | Barclays | Underweight | — |
| Oct 5, 2026 | Citigroup | Neutral | — |
| Jul 31, 2026 | TD Cowen | Hold | — |
No generated briefing is available yet.
Yahoo · Oct 23, 2026
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
Yahoo · Oct 22, 2026
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 20, 2026
Shares of healthcare company Baxter International (NYSE:BAX) fell 3.8% in the afternoon session after the U.S. Food and Drug Administration publicly posted a warning letter citing significant manufacturing and contamination-control violations at its primary Round Lake, Illinois drug facility.
ChartMill · Oct 20, 2026
S&P 500 top movers today: Equifax and Hasbro gained over 10%, while General Motors and DaVita fell more than 7% in a mixed session.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BAX.
